Abstract
RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.
Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Volume: 4 Issue: 1
Author(s): Ulrich Wullner, Inga Neef, Mehmet K. Tur and Stefan Barth
Affiliation:
Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands
Abstract: RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.
Export Options
About this article
Cite this article as:
Wullner Ulrich, Neef Inga, Tur K. Mehmet and Barth Stefan, Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002506
DOI https://dx.doi.org/10.2174/157489209787002506 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Growth Factors and Chemokines: A Comparative Functional Approach Between Invertebrates and Vertebrates
Current Medicinal Chemistry Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines
Current Women`s Health Reviews Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation
Current Medical Imaging Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Mutational Testing in Gastrointestinal Stromal Tumor
Current Cancer Drug Targets Copper(II) Complexes with Saccharinate and Glutamine as Antitumor Agents: Cytoand Genotoxicity in Human Osteosarcoma Cells
Anti-Cancer Agents in Medicinal Chemistry Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Current Signal Transduction Therapy Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology